News

Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has announced the launch of its scalable, plasmid-free manufacturing system for Adeno-associated virus (AAV). Oxgene’s new TESSA technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture...

Vaccine maker Bharat Biotech has entered into an agreement with Washington University School of Medicine in St. Louis as part of which it will conduct trials, produce and market an intranasal vaccine for COVID-19 being developed by the latter. It...

I-Mab, a clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab (also known as TJC4) to initiate a...

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the US FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time...

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. This came after the Committee for Medicinal Products...

Bristol Myers Squibb announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with...

Russia expects to register another COVID-19 vaccine candidate by mid-October, according to Russian consumer safety watchdog Rospotrebnadzor. Russia expects to register another COVID-19 vaccine candidate by mid-October, according to Russian consumer safety watchdog Rospotrebnadzor. The vaccine candidate “EpiVacCorona”, which completed...